Distribution of concurrent mutations in correlation to the functionally categorized FLT3-ITD groups
| Concurrent mutations (%) . | FLT3-ITD insertion site (%) . | P . | |||
|---|---|---|---|---|---|
| . | JMD (572-603) . | Hinge region (604-609) . | Beta1 of TKD1 (610-615) . | 3′ of beta1 (616 and C-terminal) . | |
| NPM1 | 71/115 (62) | 16/30 (53) | 29/56 (52) | 2/5 (40) | .48 |
| MLL-PTD | 7/112 (6) | 4/28 (14) | 5/55 (9) | 0/5 | .45 |
| CEBPA | 6/101 (6) | 2/25 (8) | 2/49 (4) | 0/5 | .86 |
| FLT3-TKD | 6/114 (5) | 1/30 (3) | 2/55 (4) | 0/5 | .999 |
| NRAS | 7/106 (7) | 0/23 | 2/47 (4) | 0/5 | .71 |
| Concurrent mutations (%) . | FLT3-ITD insertion site (%) . | P . | |||
|---|---|---|---|---|---|
| . | JMD (572-603) . | Hinge region (604-609) . | Beta1 of TKD1 (610-615) . | 3′ of beta1 (616 and C-terminal) . | |
| NPM1 | 71/115 (62) | 16/30 (53) | 29/56 (52) | 2/5 (40) | .48 |
| MLL-PTD | 7/112 (6) | 4/28 (14) | 5/55 (9) | 0/5 | .45 |
| CEBPA | 6/101 (6) | 2/25 (8) | 2/49 (4) | 0/5 | .86 |
| FLT3-TKD | 6/114 (5) | 1/30 (3) | 2/55 (4) | 0/5 | .999 |
| NRAS | 7/106 (7) | 0/23 | 2/47 (4) | 0/5 | .71 |
Patients with > 1 ITD were excluded.
JMD, juxtamembrane domain; TKD1, tyrosine kinase domain-1; NPM1, nucleophosmin 1; MLL-PTD, partial tandem duplications of the mixed lineage leukemia gene; CEBPA, CCAAT/enhancer binding protein alpha; FLT3-TKD, mutations in the tyrosine kinase domain of the FLT3 gene; and NRAS, neuroblastoma RAS viral oncogene homolog.